Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v16-FR | Version v15-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2023-01-04 | 2023-01-04 |
| Drug Identification Number | 02329239 | 02329239 |
| Brand name | DRAXIMAGE MDP-25 | DRAXIMAGE MDP-25 |
| Common or Proper name | DRAXIMAGE MDP-25 | DRAXIMAGE MDP-25 |
| Company Name | JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA | JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA |
| Ingredients | MEDRONIC ACID | MEDRONIC ACID |
| Strength(s) | 25MG | 25MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10X10ML | 10X10ML |
| ATC code | V09BA | V09BA |
| ATC description | ||
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2022-11-03 | 2022-11-03 |
| Actual start date | 2022-11-03 | 2022-11-03 |
| Estimated end date | 2022-12-21 | 2022-12-21 |
| Actual end date | 2022-12-21 | 2022-12-21 |
| Shortage status | Resolved | Resolved |
| Tier 3 Status | No | No |
| Company comments | Delay in release of recent manufactured batches. This shortage should not have an impact on patients since Jubilant also manufactures Draximage MDP 10 mg/vial (DIN 02329409) that is commercially available and can be used alternatively. | Delay in release of recent manufactured batches. This shortage should not have an impact on patients since Jubilant also manufactures Draximage MDP 10 mg/vial (DIN 02329409) that is commercially available and can be used alternatively. |
| Health Canada comments |